The integrated insulin area increased with the treatment but the other parameters were kept without correction (FPIR, glucose values and HbA1c)
10.1002/ddr.21391 6 AndonovaT.MuhovskiY.NaimovS.ApostolovaE.MladenovaS.DinchevaI.et al (2025)
community and clinical sources describe dermatological monitoring for these changes, especially with long-term use Injection site darkening localized hyperpigmentation Mood changes irritability reported by some during loading Managing nausea: community sources commonly describe beginning at 100-250 mcg, injecting before bed on an empty stomach, using anti-nausea medication (ondansetron) when needed, and escalating the dose gradually
Maebashi M, Kawamura N, Sato M, Imamura A, Yoshinaga K
Studies of earlier generation GLP-1 agonists show that approximately two-thirds of lost weight returns within one year of discontinuation for most individuals
If symptoms occur, stop Contrave and contact your healthcare provider